Lilly's Foundayo, Zepbound Data Show Strong Weight Loss Maintenance; Alzheimer's Drug Donanemab Enters India
LLY sits 63% above its 52-week low of $623.78.
Summary
Eli Lilly released new clinical data for its oral weight-loss pill Foundayo and its GLP-1 drug Zepbound, demonstrating strong weight loss maintenance. Foundayo patients switching from tirzepatide regained approximately 11 pounds and from semaglutide approximately 2 pounds, preserving 75% and 79% of prior loss versus placebo. Zepbound's SURMOUNT-MAINTAIN study indicated that adults on higher doses maintained near-full weight loss at 52 weeks. Concurrently, Lilly launched its Alzheimer's drug donanemab (Lormalzi) in India, priced at approximately $957 per vial. This news reinforces the long-term efficacy and market potential of Lilly's key growth drivers in the obesity market and expands the global reach of its Alzheimer's treatment. Investors will be watching the commercial uptake of donanemab in India and further detailed analyses of the Foundayo and Zepbound maintenance data.
At the time of this announcement, LLY was trading at $1,014.60 on NYSE in the Life Sciences sector, with a market capitalization of approximately $956.6B. The 52-week trading range was $623.78 to $1,133.95. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Wiseek News.